Advertisement

ريزدرونات تيڤع ٣٥ ملغ

المعلومات الرئيسية

  • اسم تجاري:
  • ريزدرونات تيڤع ٣٥ ملغ
  • الشكل الصيدلاني:
  • TABLETS
  • طريقة التعاطي:
  • PER OS
  • يسخدم من اجل:
  • البشر
  • نوع الدواء:
  • المخدرات الوباتشيك
  • المصنعة من قبل:
  • TEVA PHARMACEUTICAL WORKS PRIVATE LIMITED COMPANY, HUNGARY
Advertisement

المستندات

الأقلمة

  • متاح في:
  • ريزدرونات تيڤع ٣٥ ملغ
    إسرائيل
  • اللغة:
  • العربية

معلومات العلاجية

  • المجموعة العلاجية:
  • RISEDRONIC ACID
  • الخصائص العلاجية:
  • Treatment of postmenopausal osteoporosis to reduce the risk of vertebral fractures. Treatment of established postmenopausal osteoporosis to reduce the risk of hip fractures. Prevention of osteoporosis in postmenopausal women with increased risk of osteoporosis. Treatment of osteoporosis in men at high risk of fracture.

معلومات أخرى

الحالة

  • المصدر:
  • Ministry of Health - State of Israel
  • تخويل:
  • 96633117300
  • تاريخ الترخيص:
  • 01-10-2011
  • اخر تحديث:
  • 09-08-2016

معلومات المرضى النشرة


Risedronate teva moh, 26/12/10, SZ 

®

"# $

Risedronate Sodium     35 mg

Lactose monohydrate, pregelatinized starch, starch, colloidal silicon dioxide, sodium stearyl 

fumarate, magnesium stearate, hypromellose, titanium dioxide, macrogol/PEG 400, iron oxide 

yellow, polysorbate 80, FD&C yellow #6/sunset yellow FCF aluminum lake, iron oxide red. 

" # $ %   &

& %

" !

&   "

"

" "

" $ D

" !    

" ! ! !

& ®

"

" )

"

"

" "

Risedronate teva moh, 26/12/10, SZ 

osteonecrosis

& '

" ( %

& $ %

& ! $

+++++++++++++++++++++++++++++++++++++++++++

+++++++++++++++++++++++++++++++++++++++++++

"  

" ! "  

" )

"   " "   "

" !  

-* . / &

0&// !

11-12-2017

FDA Drug Safety Communication: FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections

FDA Drug Safety Communication: FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections

A U.S. Food and Drug Administration (FDA) safety review has resulted in adding warnings to the labels of a specific class of type 2 diabetes medicines called sodium-glucose cotransporter-2 (SGLT2) inhibitors about the risks of too much acid in the blood and of serious urinary tract infections. Both conditions can result in hospitalization.

FDA - U.S. Food and Drug Administration

7-2-2018

Protonix vs. Prevacid

Protonix vs. Prevacid

Protonix (pantoprazole sodium) and Prevacid (lansoprazole) are proton pump inhibitors (PPIs) used to treat gastroesophageal reflux disease (GERD) and a history of erosive esophagitis. Prevacid is also used to treat and prevent stomach and intestinal ulcers and other conditions involving excessive stomach acid such as Zollinger-Ellison syndrome. Protonix is available by prescription while Prevacid is available over-the-counter (OTC) and as a generic.

US - RxList

24-1-2018

ORACIT (Citric Acid And Sodium Citrate) Solution [CMP Pharma, Inc.]

ORACIT (Citric Acid And Sodium Citrate) Solution [CMP Pharma, Inc.]

Updated Date: Jan 24, 2018 EST

US - DailyMed

12-12-2017

ALPHA-PRO (Sodium Fluoride And Hydrofluoric Acid) Gel [Dental Technologies, Inc.]

ALPHA-PRO (Sodium Fluoride And Hydrofluoric Acid) Gel [Dental Technologies, Inc.]

Updated Date: Dec 12, 2017 EST

US - DailyMed

8-11-2017

Divalproex Sodium

Divalproex Sodium

Divalproex sodium is a stable coordination compound comprised of sodium valproate and valproic acid used to treat manic episodes associated with bipolar disorder, epilepsy, and migraine headaches.

US - RxList

17-10-2017

SULFZIX (Sodium Polysulthionate, Folic Acid) Capsule [Basiem]

SULFZIX (Sodium Polysulthionate, Folic Acid) Capsule [Basiem]

Updated Date: Oct 17, 2017 EST

US - DailyMed

7-9-2017

EU/3/03/182 (Idorsia Pharmaceuticals Deutschland GmbH)

EU/3/03/182 (Idorsia Pharmaceuticals Deutschland GmbH)

EU/3/03/182 (Active substance: 5-methyl-pyridine-2-sulfonic acid {6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-[2-(1H-tetrazol-5-yl)-pyridin-4-yl]-pyrimidin-4-yl}-amide sodium salt) - Transfer of orphan designation - Commission Decision (2017)6106 of Thu, 07 Sep 2017 European Medicines Agency (EMA) procedure number: EMEA/OD/057/03/T/02

Europe -DG Health and Food Safety

28-8-2017

AX PHARMACEUTICAL CORP (Hyaluronate Acid Sodium) Powder [AX Pharmaceutical Corp]

AX PHARMACEUTICAL CORP (Hyaluronate Acid Sodium) Powder [AX Pharmaceutical Corp]

Updated Date: Aug 28, 2017 EST

US - DailyMed

23-5-2017

EU/3/17/1876 (TMC Pharma Services Ltd)

EU/3/17/1876 (TMC Pharma Services Ltd)

EU/3/17/1876 (Active substance: Sodium (1R,3R,4R,5S)-3-({2-N-acetylamino-2-deoxy-3-O-[(1S)-1-carboxylato-2-cyclohexylethyl]-beta-D-galactopyranosyl}oxy)-4-({6-deoxy-alpha-L-galactopyranosyl}oxy)-5-ethyl-cyclohexan-1-yl-(38-oxo-2,5,8,11,14,17,20,23,26,29,32,35-dodecaoxa-39-azahentetracontan-41-yl)carboxamide) - Orphan designation - Commission Decision (2017)3609 of Tue, 23 May 2017 European Medicines Agency (EMA) procedure number: EMA/OD/010/17

Europe -DG Health and Food Safety

Advertisement